Pantothenic acid (vitamin B5): food, adequate-intake estimates, deficiency, pantethine, acne research, and evidence limits

Nutrition and treatment claims differ

A wide range of foods contains B5

NIH lists poultry, meat, seafood, eggs, milk, whole grains, mushrooms, avocados, potatoes, legumes, peanuts and sunflower seeds among sources. A varied diet can supply B5 from several food groups. Its presence in an energy drink does not make that drink necessary for adequacy or establish a benefit from the drink’s other ingredients.[2]

Naming a form does not prove it is superior

NIH describes pantothenate and pantethine supplements but lacks comparative bioavailability studies. A chemical-form claim does not establish superiority for a clinical outcome.[1]

Deficiency is unusual and often occurs with wider malnutrition

NIH describes deficiency mainly in severe malnutrition or historical experimental deprivation, often alongside other nutrient deficiencies. Burning or numb hands and feet, fatigue and digestive symptoms have been reported in those contexts. These symptoms are not specific enough to identify B5 deficiency in an otherwise unassessed person, and a burning-feet advertisement should not substitute for considering other causes.[1]

A rare coenzyme-pathway disorder is not ordinary low intake

PANK2 mutations can cause pantothenate kinase-associated neurodegeneration, or PKAN, affecting a step involved in coenzyme A production. NIH describes neurological manifestations and uncertainty about benefit from ordinary pantothenate supplementation. A genetically impaired pathway and insufficient food intake are different problems. A biochemical rationale or anecdote does not establish a treatment for that rare disease.[1]

An adequate intake is an estimate, not a measured minimum

EFSA’s 2014 opinion based its adequate-intake estimate on observed intakes and the apparent absence of deficiency in European populations. It could not establish an average requirement or population reference intake from the available evidence. This distinction explains why a table can publish a value even when the precise requirement has not been directly established.[3]

A test may reflect intake without validating an optimal target

EFSA describes urinary and blood measurements as possible indicators of intake, while noting inadequate evidence on their variability and ability to separate sufficiency from insufficiency. It had no established biomarker cutoffs for deriving requirements. The ability to measure B5 therefore does not validate a personal “optimal” concentration or prove that changing the number improves symptoms.[3]

Very high supplemental amounts can still cause adverse effects

NIH describes digestive discomfort and diarrhea with very large supplemental amounts, despite the absence of an established upper intake limit. A missing limit reflects the state of the evidence, rather than a tested permission for unlimited dosing. Safety during a small short trial cannot settle uncommon adverse effects or the consequences of taking a product for years.[2]

A pathway disorder differs from too little dietary vitamin

Pantothenate kinase-associated neurodegeneration is caused by PANK 2 variants affecting an enzyme involved in coenzymeA production. MedlinePlus describes progressive neurological symptoms and abnormal brain iron accumulation. An inherited disruption of this pathway is different from inadequate dietary pantothenic acid. Naming the vitamin-related enzyme does not demonstrate that ordinaryB 5 supplements correct the genetic disorder or treat unexplained fatigue.[6]

Published questions

The pantethine trial measured cholesterol rather than clinical events

A 2014 trial randomized 32 participants after a dietary lead-in and compared pantethine with placebo for sixteen weeks. Twenty-four completed supplementation. It reported improvement in selected lipid measurements, including LDL cholesterol, in a population classified as having low to moderate cardiovascular risk under older criteria. It did not establish prevention of heart attacks, strokes or death.[4]

Diet changes, the small sample, incomplete follow-up and multiple measured outcomes matter when interpreting the result. Pantethine is a related compound rather than the same exposure as ordinary food B5. The paper includes authors affiliated with ingredient companies; a complete sponsor-role and bias appraisal remains outstanding. Its lipid result is not evidence to replace an established preventive treatment.[4]

A small formulation trial offers a signal, not a settled treatment

A 2014 placebo-controlled study enrolled 48 people with mild to moderate facial acne; 41 were evaluable. After twelve weeks, the B5-based supplement group had a greater reduction in total lesion count and improvement in selected secondary measures. The authors described tolerability during that study and called for further trials. A single short trial does not establish a universal acne treatment.[5]

The tested formulation, selected participants and lesion-count endpoint are important. The complete ingredient-level attribution, allocation details, missing-participant analysis and sponsor role were not independently appraised here. It would be misleading to turn this study into proof that every isolated B5 product works, that it outperforms established acne care or that longer high-dose use is harmless.[5]

A supplement review needs the actual product

NIH does not identify established clinically relevant medicine interactions for B5, but advises discussing supplements and medicines together. That does not certify every multi-ingredient formulation. A product may contain other vitamins, minerals or substances with their own exposure and interaction questions. Its entire ingredient list matters alongside the proposed B5 benefit.[2]

References

1. Pantothenic Acid: Health Professional Fact Sheet

   Agency condition or prevention explanation

   NIH Office of Dietary Supplements · Content/publication date: not stated
   Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
   Cited sections: Coenzyme role, supplement comparisons, rare deficiency and PKAN distinction

2. Pantothenic Acid: Consumer Fact Sheet

   Agency condition or prevention explanation

   NIH Office of Dietary Supplements · Content/publication date: not stated
   Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
   Cited sections: Food distribution, very-high-intake digestive effects and supplement context

3. Scientific Opinion on Dietary Reference Values for pantothenic acid

   Agency scientific opinion

   EFSA NDA Panel · Content/publication date: 2014
   Accessed: 2026-10-09 UTC · Original final-opinion PDF abstract and summary inspected; complete evidence appraisal pending
   Cited sections: Final February 2014 opinion: abstract/summary, adequate-intake basis and biomarker limits

4. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy

   Randomized trial

   Evans M and colleagues · Content/publication date: 2014
   Accessed: 2026-10-09 UTC · Original abstract and selected original methods/results/affiliations inspected; full sponsor-role and bias appraisal pending
   Cited sections: 2014: original abstract, selected methods/results and author affiliations

5. A randomized, double-blind, placebo-controlled study of a novel pantothenic acid-based dietary supplement in subjects with mild to moderate facial acne

   Randomized trial

   Yang M and colleagues · Content/publication date: 2014
   Accessed: 2026-10-09 UTC · Original indexed abstract and selected original summary inspected; direct full-text access blocked
   Cited sections: 2014: 48 enrolled, 41 evaluable, twelve-week lesion-count outcome

   Formulation-specific result; full ingredient attribution and sponsor appraisal remain incomplete.

6. Pantothenate kinase-associated neurodegeneration

   Agency genetic explanation

   MedlinePlus Genetics / National Library of Medicine · Content/publication date: not stated
   Accessed: 2026-10-13 UTC · Original relevant abstract or source text retrieved and inspected
   Cited sections: Causes: PANK 2 enzyme, coenzymeA pathway and inherited disease; 2021 page

   Added targeted evidence or explanation; no exhaustive current appraisal.

Scope & review

Population

Readers exploring B5 nutrition; selected acne, lipid-marker and rare genetic contexts are distinguished

Exposure or intervention

Food, nutrient forms, adequate-intake assumptions, deficiency and small formulation-specific studies

Comparison

Source-specific symptom, care, screening or comparator settings

Outcomes

Adequacy, digestive harms, acne lesions and lipid markers rather than established cardiovascular-event prevention

Timeframe

Daily nutrition; selected twelve- and sixteen-week trials and dated 2014 intake appraisal

Jurisdiction

Selected US/UK agency and US/European professional guidance; jurisdiction and eligibility differences are labeled

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

What this article still leaves open

• Full ingredient, sponsor-role and bias appraisal, contemporary acne replication and event-based pantethine evidence remain outstanding.
• Specialist PKAN treatment trials, contemporary nutrient-status validation and special nutritional populations need expansion.
• Qualified review, personal deficiency diagnosis and acne, lipid or supplement regimens are not supplied.

Related reading

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.